Our data presented herein demonstrated that survivin was highly expressed specifically in LSC-enriched fractions and in approximately 85% of CD34+ AML patients compared to their differentiated counterparts, thereby contributing to drug resistance. This evidence concerns the gene BIRC5 and acute myeloid leukemia.